Nine cases of erythrodermic psoriasis treated with interleukin-17A inhibitors and literature review
YANG Jinglu
GU Jingxin
FENG Yujuan
ZHANG Shifa
Abstract：Objective To investigate the clinical efficacy and safety of interleukin(IL)-17A inhibitors(secukinumab or ixekizumab)in treating erythrodermic psoriasis(EP).Methods A retrospective analysis was performed on the clinical data of 9 EP patients treated in our hospital,summarizing the changes in Psoriasis Area and Severity Index(PASI)scores before and after IL-17A inhibitor therapy,as well as the occurrence of adverse events.Results At week 4 of IL-17A inhibitor treatment,1 patient achieved PASI 75,1 achieved PASI 90,and 3 achieved PASI 100 among the 9 EP patients.By week 8,1 patient had PASI 75 and 6 had PASI 100.At week 12,2 patients had PASI 75 and 6 had PASI 100.During treatment,only 1 patient experienced a mild upper respiratory infection with transient exacerbation of skin lesions,which resolved after symptomatic treatment.No severe adverse events occurred.Conclusion IL-17A inhibitors demonstrate rapid onset,significant efficacy,and high safety in treating erythrodermic psoriasis,with no severe adverse reactions.
Keywords：Erythrodermic psoriasisInterleukin-17A inhibitorsSecukinumabIxekizumab
Publication Date：2025-08-10
Online Publishing Date：2025-09-01(First online date of this platform, not the publication date of the document)
Pages：5( 309-313 )